GeoVax Q2 net loss $5.4M; cash $3.1M; BARDA contract terminated; GEO-MVA gets EU guidance

GeoVax Labs, Inc.

Net loss $5.37M ($0.35/share) vs $5.06M ($1.99/share) in Q2 2024; per-share loss down on share dilution.
Revenue from BARDA/RRPV contract $852k; BARDA terminated contract for convenience in Q2.
Cash $3.09M at June 30; completed July 2025 public offering netting ~$5.6M.
GEO-MVA received favorable EMA guidance allowing single Phase 3 immuno-bridging trial; trial expected 2H 2026.
GEO-CM04S1 showed superior T-cell responses vs mRNA in CLL; mRNA arm failed endpoint, enrollment restricted to GEO-CM04S1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.